Can a Lab-Made protein restore immune defenses in glioma patients?
NCT ID NCT03687957
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a drug called rhIL-7-hyFc can safely increase lymphocyte counts in people with high-grade glioma who have low immune cells after standard radiation and chemotherapy. About 42 participants will receive either the drug or a placebo by injection. The study first checks safety and dosing, then measures changes in immune cell levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rhIL-7-hyFc (a lab-made protein that may help increase immune cell counts)
What this could lead to
If it works, this could point toward a way to restore immune function in brain cancer patients, potentially helping them fight infections and better tolerate treatment.
What could go wrong
This is a very early, small trial (42 people) testing safety and immune effects, not whether it improves survival. The drug may cause side effects or fail to raise lymphocyte levels meaningfully.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States